CA3115342A1 - Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases - Google Patents
Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases Download PDFInfo
- Publication number
- CA3115342A1 CA3115342A1 CA3115342A CA3115342A CA3115342A1 CA 3115342 A1 CA3115342 A1 CA 3115342A1 CA 3115342 A CA3115342 A CA 3115342A CA 3115342 A CA3115342 A CA 3115342A CA 3115342 A1 CA3115342 A1 CA 3115342A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- mice
- donecopride
- neurons
- radical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306280.1 | 2018-09-28 | ||
| EP18306280.1A EP3628660A1 (en) | 2018-09-28 | 2018-09-28 | Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases |
| PCT/EP2019/076229 WO2020065028A1 (en) | 2018-09-28 | 2019-09-27 | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3115342A1 true CA3115342A1 (en) | 2020-04-02 |
Family
ID=63798921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3115342A Pending CA3115342A1 (en) | 2018-09-28 | 2019-09-27 | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220031680A1 (https=) |
| EP (2) | EP3628660A1 (https=) |
| JP (1) | JP2022511366A (https=) |
| KR (1) | KR20210098429A (https=) |
| CN (1) | CN113195452A (https=) |
| AU (1) | AU2019346024B2 (https=) |
| BR (1) | BR112021005952A2 (https=) |
| CA (1) | CA3115342A1 (https=) |
| SG (1) | SG11202103070VA (https=) |
| WO (1) | WO2020065028A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3166060A1 (fr) | 2024-09-12 | 2026-03-13 | Université De Caen Normandie | Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative |
| FR3166146A1 (fr) | 2024-09-12 | 2026-03-13 | Université De Caen Normandie | Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| FR2904113A1 (fr) | 2006-07-21 | 2008-01-25 | Exonhit Therapeutics S A Sa | Procedes et outils pour la therapie de pathologies neurodegeneratives |
| CN102355902A (zh) * | 2009-01-24 | 2012-02-15 | 植物药物公共有限公司 | 神经营养因子介导的病症的处理 |
| FR3006686A1 (fr) * | 2013-06-05 | 2014-12-12 | Univ Caen | Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant |
| KR101824154B1 (ko) * | 2013-12-16 | 2018-03-14 | 수벤 라이프 사이언시스 리미티드 | 5-ｈｔ４ 수용체 작용제로서 인다졸 화합물 |
-
2018
- 2018-09-28 EP EP18306280.1A patent/EP3628660A1/en not_active Withdrawn
-
2019
- 2019-09-27 US US17/280,217 patent/US20220031680A1/en not_active Abandoned
- 2019-09-27 BR BR112021005952-0A patent/BR112021005952A2/pt unknown
- 2019-09-27 KR KR1020217009149A patent/KR20210098429A/ko not_active Ceased
- 2019-09-27 EP EP19783459.1A patent/EP3856716A1/en active Pending
- 2019-09-27 SG SG11202103070VA patent/SG11202103070VA/en unknown
- 2019-09-27 CN CN201980063618.3A patent/CN113195452A/zh active Pending
- 2019-09-27 CA CA3115342A patent/CA3115342A1/en active Pending
- 2019-09-27 JP JP2021517453A patent/JP2022511366A/ja active Pending
- 2019-09-27 AU AU2019346024A patent/AU2019346024B2/en not_active Ceased
- 2019-09-27 WO PCT/EP2019/076229 patent/WO2020065028A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020065028A1 (en) | 2020-04-02 |
| AU2019346024B2 (en) | 2024-07-18 |
| JP2022511366A (ja) | 2022-01-31 |
| EP3628660A1 (en) | 2020-04-01 |
| AU2019346024A1 (en) | 2021-04-29 |
| SG11202103070VA (en) | 2021-04-29 |
| BR112021005952A2 (pt) | 2021-06-29 |
| KR20210098429A (ko) | 2021-08-10 |
| US20220031680A1 (en) | 2022-02-03 |
| CN113195452A (zh) | 2021-07-30 |
| EP3856716A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Medrano-Jiménez et al. | Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism | |
| Pierzynowska et al. | Autophagy-dependent mechanism of genistein-mediated elimination of behavioral and biochemical defects in the rat model of sporadic Alzheimer's disease | |
| Corpas et al. | SIRT1 overexpression in mouse hippocampus induces cognitive enhancement through proteostatic and neurotrophic mechanisms | |
| Urano et al. | Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy | |
| Park et al. | Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation | |
| Easton et al. | Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer’s disease | |
| US9603869B2 (en) | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders | |
| AU2019346024B2 (en) | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases | |
| US20220119765A1 (en) | Differentiation method of neural stem cells manufactured by direct cell conversion into astrocytes | |
| US20210038589A1 (en) | Uses, compositions and methods | |
| Cho et al. | Phyllodulcin improves hippocampal long-term potentiation in 5XFAD mice | |
| US20210338647A1 (en) | Combination of Acetylcholinesterase Inhibitor and 5-HT4 Receptor Agonist As Neuroprotective Agent In the Treatment of Neurodegenerative Diseases | |
| KR20200116054A (ko) | 봉독 추출물을 유효성분으로 함유하는 신경염증 질환 예방 또는 치료용 조성물 | |
| WO2023078325A1 (zh) | 一种含有依达拉奉右莰醇组合物在治疗认知障碍中的应用 | |
| RU2800802C2 (ru) | Донекоприд как нейропротекторный агент при лечении нейродегенеративных заболеваний | |
| US10618937B2 (en) | Method of treating Alzheimer's disease | |
| JP7249433B2 (ja) | 蜂毒抽出物を有効成分として含有する神経炎症疾患の予防または治療用組成物 | |
| Lorke et al. | α7-nicotinic acetylcholine receptors and β-amyloid peptides in Alzheimer’s disease | |
| Liu et al. | Blockage of IL-17 ameliorates Aβ-induced neurotoxicity and cognitive decline | |
| US12605358B2 (en) | Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient | |
| Wang et al. | Neuroprotective Effect of Hydroxysafflor Yellow A on an Alzheimer’s Disease (AD)-Like Mouse Model | |
| Yang et al. | Benzene, 1, 2, 4-Trimethoxy-5-(2-Methyl-1-Propen-1-yl) Attenuates D-galactose/AlCl3-induced Cognitive Impairment by Inhibiting Inflammation, Apoptosis, and improving Expression of Memory-Related Proteins | |
| Tan et al. | Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240809 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240809 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240916 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240916 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240916 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250806 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251113 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20251208 |